Manufacturing of life-enhancing medicines boosted by new government funding

22 Nov 2018

Patients could receive faster treatment following boost to streamline the production of medicines and treatments.

Patients could soon receive faster treatment thanks to a multimillion pound government boost to streamline the production of medicines and treatments, including those used to treat blood cancers and inherited disorders.

Manufacturing of life-enhancing medicines boosted by new government funding

Companies in Northumberland, Oxford and London will adopt new digital technologies, such as artificial intelligence, to support the manufacture of next-generation medicines and treatments.

The £4.3 million funding aims to create more efficient and innovative methods for manufacturing medicines. The challenge works to set the UK apart as a leader with greater capacity for manufacture of safe, affordable and effective therapies.

Life Sciences Minister Lord Henley said: "New technology can help us live longer, healthier lives and the new projects announced today will improve the speed and accuracy with which medicines get to the people that need them.

"Advances in technology can help us address the challenges that an ageing society presents and we are backing the technologies of tomorrow in our modern Industrial Strategy, with the biggest increase in public research and development investment in UK history."

The three individual projects are:

  • Arc Trinova in Northumberland will use new technologies to speed up the process of the production of patient-specific medicines; it is currently a timely process dispensing individual doses from bulk because of the careful handling, labelling and batch release processes.
  • Oxford Biomedica will look to dramatically reduce the supply time for manufacturing by using a new digital and robotics framework to increase capacity, reduce waste and cut costs.
  • Autolus in London will look to avoid mix-ups of complex medicines on the supply chain by developing a computer-based system that will constantly monitor the operation, making adjustments to timing, co-ordination and production where necessary, improving the efficiency of the whole system and working at a pace that human operators cannot imitate.
  • One year on from the launch of the Industrial Strategy, this £7.3 million investment is the latest commitment from the £180 million Industrial Strategy Challenge Fund (ISCF) dedicated to leading-edge Medicines Manufacturing.

    Taking steps to improve patient access to life-saving treatments and medicines, Advanced Therapy Treatment Centres, working across the UK, will support the roll-out of cell and gene therapies as clinical trials show them to be safe and cost-effective. The centres bring together expert clinicians, researchers, scientists, developers and private companies to demonstrate how the therapies have impact on patients’ lives.

    Advanced therapies, including cell and gene therapies, represent the next generation of therapies that have the potential to offer treatments for a number of conditions including some blood cancers and inherited conditions for which there are currently limited treatment options.

    UK Research and Innovation (UKRI) is responsible for managing the Industrial Strategy Challenge Fund, which funds the winners of the Medicines Manufacturing Challenge.

    Dr Ian Campbell, Interim Executive Chair, Innovate UK for UKRI, said: "The projects announced today will bring real benefits to patients and boost the knowledge economy as part of the government’s modern Industrial Strategy. This is vital for the UK as a global leader in the development of advanced therapies and medicine manufacturing."

    Read More

    Related news

    Chemspace and LabNetwork collaborate to extend access to chemical databases

    Chemspace and LabNetwork collaborate to extend access to chemical databases

    14 Feb 2019

    Collaboration provides drug discovery researchers access to European distribution and local support for library of in-stock and on-demand compounds.

    Read more 
    SGS to conduct its first malaria human challenge trial in Belgium

    SGS to conduct its first malaria human challenge trial in Belgium

    13 Feb 2019

    The advanced candidate compound undergoing the trial has demonstrated potential to target malaria parasites before they have a chance to establish the symptoms of malaria.

    Read more 
    Post-EU FMD deadline - 'business as usual'?

    Post-EU FMD deadline - 'business as usual'?

    12 Feb 2019

    Partner connectivity will be an immediate and ongoing challenge beyond the deadline and several pharma companies are likely to break agreements with current suppliers through breach of contract clauses.

    Read more 
    BASF opens Application Technology Laboratory for personal care in Nigeria

    BASF opens Application Technology Laboratory for personal care in Nigeria

    11 Feb 2019

    Local competence in application and formulation technology for sub-Saharan African personal care market.

    Read more 
    FDA approves first Nanobody-based medicine for adults with aTTP

    FDA approves first Nanobody-based medicine for adults with aTTP

    10 Feb 2019

    Cablivi is the first US approval for Sanofi's new rare blood disorders franchise.

    Read more 
    Pharmapack Europe 2019 Award Winners

    Pharmapack Europe 2019 Award Winners

    7 Feb 2019

    Awards showcased a wide range of industry-changing discoveries in drug delivery, packaging and automation.

    Read more 
    Brexit - the EU FMD's painful problem

    Brexit - the EU FMD's painful problem

    7 Feb 2019

    Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

    Read more 
    New series of advanced freeze dryers

    New series of advanced freeze dryers

    6 Feb 2019

    The LyoConstellation series allows the development of highly aggressive cycles and the mapping of the furthest reaches of theoretical design space for a formulation.

    Read more 
    Hitachi Chemical to acquire apceth Biopharma

    Hitachi Chemical to acquire apceth Biopharma

    5 Feb 2019

    Acquisition will strengthen Hitachi's presence in the second-largest cell and gene therapy market in the world.

    Read more 
    FDA approves first generic Advair Diskus

    FDA approves first generic Advair Diskus

    4 Feb 2019

    Mylan's Wixela Inhub is the first FDA-approved therapeutically equivalent generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or COPD.

    Read more